605 related articles for article (PubMed ID: 11129127)
1. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
4. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L
Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644
[TBL] [Abstract][Full Text] [Related]
8. Cerivastatin.
Cheng-Lai A
Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies.
Hunninghake DB
Am J Cardiol; 1998 Aug; 82(4B):26J-31J. PubMed ID: 9737643
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.
Isaacsohn J; Insull W; Stein E; Kwiterovich P; Patrick MA; Brazg R; Dujovne CA; Shan M; Shugrue-Crowley E; Ripa S; Tota R;
Clin Cardiol; 2001 Sep; 24(9 Suppl):IV1-9. PubMed ID: 11594407
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group.
Ose L; Luurila O; Eriksson J; Olsson A; Lithell H; Widgren B
Curr Med Res Opin; 1999; 15(3):228-40. PubMed ID: 10621930
[TBL] [Abstract][Full Text] [Related]
13. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
14. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group.
Betteridge DJ
Int J Clin Pract; 1999 Jun; 53(4):243-50. PubMed ID: 10563066
[TBL] [Abstract][Full Text] [Related]
15. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Stein E
Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
[TBL] [Abstract][Full Text] [Related]
16. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
Farnier M
Am J Cardiol; 1998 Aug; 82(4B):47J-51J. PubMed ID: 9737646
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin: a review of its use in the management of dyslipidemia.
Scott LJ; Curran MP; Figgitt DP
Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group.
Dujovne CA; Knopp R; Kwiterovich P; Hunninghake D; McBride TA; Poland M
Mayo Clin Proc; 2000 Nov; 75(11):1124-32. PubMed ID: 11075741
[TBL] [Abstract][Full Text] [Related]
19. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Stein E
Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
